Protocol‐based nurse coordinator management of ambulatory tacrolimus dosing in de novo renal transplant recipients—A single‐center experience with a large African American population

Transplant nurse (RN) coordinators review tacrolimus levels frequently and would be capable of making dose adjustments autonomously if not limited by their license. Collaborative practice agreements could be an answer; thus, the aim of this evaluation was to determine if an RN‐driven protocol could be used safely and effectively to manage tacrolimus in ambulatory kidney transplant (KTX) recipients.

[1]  A. Maldonado,et al.  Impact of CYP3A5 genomic variances on clinical outcomes among African American kidney transplant recipients , 2018, Clinical transplantation.

[2]  T. Srinivas,et al.  Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation , 2017, Transplantation.

[3]  A. Maldonado,et al.  Prevalence of CYP3A5 Genomic Variances and Their Impact on Tacrolimus Dosing Requirements among Kidney Transplant Recipients in Eastern North Carolina , 2017, Pharmacotherapy.

[4]  W. Guan,et al.  Genotype-guided tacrolimus dosing in African American kidney transplant recipients , 2015, The Pharmacogenomics Journal.

[5]  M. Gebregziabher,et al.  African‐American Race Modifies the Influence of Tacrolimus Concentrations on Acute Rejection and Toxicity in Kidney Transplant Recipients , 2015, Pharmacotherapy.

[6]  S. Aliño,et al.  Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies , 2014, The Pharmacogenomics Journal.

[7]  M. Pepper,et al.  Cytochrome P450 pharmacogenetics in African populations , 2013, Drug metabolism reviews.

[8]  R. Colvin,et al.  Banff 2011 Meeting Report: New Concepts in Antibody‐Mediated Rejection , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  O. Pankewycz,et al.  A prospective protocol-based trial of darbepoetin alfa therapy to correct the early anemia following renal transplantation. , 2010, Transplantation proceedings.

[10]  Tanya D. Williams,et al.  Nurse-driven intravenous heparin protocol: quality improvement initiative. , 2010, AACN advanced critical care.

[11]  H. E. Hansen,et al.  The Banff 97 working classification of renal allograft pathology. , 1999, Kidney international.